Hanson & Doremus Investment Management boosted its stake in shares of Eli Lilly And Co (NYSE:LLY) by 6.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,404 shares of the company’s stock after purchasing an additional 347 shares during the quarter. Hanson & Doremus Investment Management’s holdings in Eli Lilly And Co were worth $710,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in the business. Selective Wealth Management Inc. bought a new stake in shares of Eli Lilly And Co in the third quarter valued at approximately $25,000. Enterprise Trust & Investment Co bought a new stake in shares of Eli Lilly And Co in the third quarter valued at approximately $27,000. Garrett Wealth Advisory Group LLC bought a new stake in shares of Eli Lilly And Co in the third quarter valued at approximately $29,000. Candriam Luxembourg S.C.A. boosted its position in shares of Eli Lilly And Co by 47.7% in the third quarter. Candriam Luxembourg S.C.A. now owns 270,304 shares of the company’s stock valued at $30,000 after acquiring an additional 87,250 shares during the period. Finally, Prestige Wealth Management Group LLC bought a new stake in shares of Eli Lilly And Co in the second quarter valued at approximately $34,000. 76.45% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have recently weighed in on LLY shares. Morgan Stanley raised Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $116.00 to $150.00 in a research report on Wednesday, December 18th. They noted that the move was a valuation call. Argus increased their price objective on Eli Lilly And Co from $145.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, December 30th. Cantor Fitzgerald reissued a “buy” rating and issued a $143.00 price objective on shares of Eli Lilly And Co in a research report on Monday, December 2nd. Bank of America started coverage on Eli Lilly And Co in a research report on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price objective for the company. Finally, UBS Group reduced their price objective on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research report on Thursday, October 17th. Five research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $135.67.
Shares of NYSE LLY traded down $1.04 during trading hours on Thursday, reaching $140.95. The stock had a trading volume of 52,606 shares, compared to its average volume of 3,224,563. The business’s fifty day moving average is $127.65 and its two-hundred day moving average is $115.42. The company has a debt-to-equity ratio of 4.09, a current ratio of 1.17 and a quick ratio of 0.88. The company has a market cap of $135.04 billion, a price-to-earnings ratio of 25.41, a PEG ratio of 1.84 and a beta of 0.20. Eli Lilly And Co has a twelve month low of $101.36 and a twelve month high of $141.69.
Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Wednesday, October 23rd. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.05. The business had revenue of $5.48 billion during the quarter, compared to analyst estimates of $5.50 billion. Eli Lilly And Co had a return on equity of 107.99% and a net margin of 35.10%. Eli Lilly And Co’s revenue was up 3.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.39 earnings per share. Sell-side analysts forecast that Eli Lilly And Co will post 5.8 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 14th will be paid a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a dividend yield of 2.10%. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.65. The ex-dividend date of this dividend is Thursday, February 13th. Eli Lilly And Co’s dividend payout ratio is presently 46.49%.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
See Also: Golden Cross
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.